Testosterone therapy and venous thromboembolism: A systematic review and meta-analysis

Damon E. Houghton a,⁎, Mouaz Alsawas b, Patricia Barrioneuvo b, Mouaffaa Tello b, Wigdan Farah b, Brad Beuscher b, Larry J. Prokop d, J. Bradley Layton c, M. Hassan Murad b, Stephan Moll e

a Mayo Clinic, Department of Cardiovascular Diseases, Division of Vascular Medicine & Department of Internal Medicine, Division of Hematology/Oncology, 200 1st St SW, Rochester, MN 55905, USA
b Mayo Clinic, Evidence-based Practice Center, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, 200 1st St SW, Rochester, MN 55901, USA
c RTI Health Solutions, Research Triangle Park, NC 27709-2194, USA
d Mayo Clinic Libraries, 200 1st St SW, Rochester, MN 55901, USA
e University of North Carolina School of Medicine, Department of Medicine, Division of Hematology/Oncology, Chapel Hill, NC, USA

ARTICLE INFO

Keywords:
Testosterone
Thrombosis
Venous thromboembolism
Hypercoagulability

ABSTRACT

Background: Testosterone prescribing for men has dramatically increased, and there have been concerns about inappropriate use and adverse events. While regulatory bodies have warned about increased risk of venous thromboembolism (VTE), published clinical data supporting an increased risk for VTE are limited.

Objective: To conduct a systematic review of studies examining the association between testosterone therapy in men and VTE.

Methods: Comprehensive searches of multiple databases were performed from inception through October 3rd, 2018. Randomized control trials (RCTs) and observational studies examining the association between exogenous testosterone (any route) and VTE. Study selection and data extraction were performed by two independent investigators. Random-effect model meta-analyses were used to estimate pooled odds ratios (OR) and 95% confidence intervals (CIs). Heterogeneity among studies was evaluated using the I² statistic. Risk of bias was assessed using the Cochrane and Newcastle-Ottawa tools.

Results: Six RCTs (n = 2236) and 5 observational studies (n = 1,249,640) were included. Five RCTs were performed in men with documented hypogonadism. The observational studies included: 2 case-control studies, 2 retrospective cohorts, and 1 retrospective cohort with a nested case-control study. There was no evidence of a statistically significant association between VTE and testosterone (OR 1.41, 95%CI 0.96–2.07). Heterogeneity was high (I-squared = 84.4%). The association remained nonsignificant when the analysis was stratified by study design: RCTs (2.05, 95% CI 0.78–5.39); cohort (1.06, 95% CI 0.85–1.33); and case-control (1.34, 95% CI 0.78–2.28). The overall risk of bias was moderate.

Conclusions: The current evidence is of low certainty but does not support an association between testosterone use and VTE in men.

1. Introduction

Testosterone therapy has rapidly expanded over the past decades [3–7], and there are concerns over inappropriate prescribing and adverse effects [8], including venous thromboembolism (VTE). Upward trends in testosterone use are seen in numerous countries, but rates of prescribing are highest in the United States, having risen from 20.2 per 10,000 person-years in 2008 to 75.7 per 10,000 person-years in 2011 [3]. An increasing trend in prescribing has continued from 2010 to 2013 as shown by FDA data from testosterone sales [9], although data from US commercial insurance claims indicate a downward trend in new testosterone users starting July 2012 and continuing through 2013 [10].

Testosterone is indicated for the treatment of primary or secondary hypogonadism in men, but potentially inappropriate prescribing of testosterone has been demonstrated by studies that estimate that 25–50% of new-users did not have a pre-treatment serum testosterone level [3,9,11]. Much of the prescribing occurs in middle-aged to older men who are already at a higher risk of venous thromboembolism due...
to their age and comorbidities, making it difficult for clinicians to understand whether testosterone use is truly a contributor to thrombotic events, or simply coincidental. Current labeling for testosterone products in the United States warns against VTE, and the warning was expanded in 2014 to include all testosterone users rather than only patients who develop erythrocytosis [12]. This article will first discuss possible mechanisms by which testosterone may contribute to VTE and then systematically review the current literature to determine the association between exogenous testosterone use and VTE in men.

1.1. Proposed mechanisms of thrombosis

Erythrocytosis: The Food and Drug Administration requires a warning in the labeling of testosterone products of VTE risk as a possible consequence of erythrocytosis, but also of increased VTE risk independent of erythrocytosis [13]. While testosterone therapy clearly and consistently increases hemoglobin concentrations and can lead to erythrocytosis [14–18], no data have been published that show an association of testosterone-induced erythrocytosis with VTE risk. An Endocrine Society Clinical Practice Guideline recommends avoiding testosterone therapy in patients with baseline erythrocytosis (hematocrit > 50%) and monitoring for a rise in hematocrit in new users 3 and 6 months after initiation, and then annually [1]. Testosterone dose reduction and/or discontinuation is recommended if a patient develops erythrocytosis.

In most reports of VTE associated with testosterone use, erythrocytosis was not present or not reported [19–23]. Only one case report has been published about a patient taking testosterone with an otherwise unprovoked mesenteric vein thrombosis in the setting of erythrocytosis (hemoglobin 19.7 g/dL) [24]. Several large cohort studies have specifically examined hemoglobin/hematocrit as a VTE risk factor with differing conclusions. In the Tromsø study [25], men with a hemoglobin ≥15.6 g/dL had an increased risk for total VTE (HR 1.6, 95% CI 1.14–2.24) and unprovoked VTE (HR 2.20, 95% CI 1.34–3.61). Other studies have not found an association between erythrocytosis and VTE [26,27], or only found an association in women [28]. Erythrocytosis has been shown to increase erythrocyte aggregation and increase blood viscosity [29], but whether this translates into a pro-coagulant effect is not known. Erythrocytosis in mouse models of arterial thrombosis have demonstrated a faster rate of thrombus formation and a shorter time to artery occlusion [30]. More research is needed to explore the role of erythrocytosis in the pathogenesis of VTE and to understand if it might lead to an increased risk for VTE in patients taking testosterone therapy.

Other mechanisms: Testosterone is partly converted to 17β-estradiol (E2) and dihydrotestosterone (DHT) in adipose tissue and it has been speculated that the increasing E2 levels may lead to thrombosis [22]. Increasing doses of testosterone are associated with higher E2 levels, and older men have a higher rate of aromatization, largely due to a higher percentage of adipose tissue [31]. Some randomized clinical trials have demonstrated higher levels of estradiol in subjects receiving testosterone [16,32] but others have not [33]. Platelet thromboxane A2 receptor density and maximum platelet aggregation response have been shown to be increased in healthy male volunteers given intramuscular testosterone [34]. How this might contribute to the development of VTE is unknown. It has also been proposed that previously undiagnosed inherited thrombophilia might compound the effects of testosterone [20,21]. Testosterone users with VTE, when compared to controls with unprovoked VTE, were more likely to have Factor V Leiden or a lupus anticoagulant [35].

2. Methods

2.1. Data sources

A search of several databases from each database’s inception, any language, was conducted in Ovid Epub Ahead of Print, Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategies were designed and conducted by an experienced librarian with input from study investigators. Controlled vocabulary supplemented with keywords was used to search for relevant studies, through October 3rd, 2018. The actual search strategy is available in the appendix. Previous systematic reviews on testosterone and VTE were identified by searching PubMed and their bibliography was reviewed for possible inclusion.

2.2. Study selection

Observational studies were eligible for inclusion if they met the following criteria: 1) cohort study or case-control study examining the association between testosterone therapy and VTE, 2) testosterone users were compared to non-users for cohort studies and subjects with VTE compared to subjects without VTE for case-control studies. All randomized control trials (RCTs) were included if VTE outcomes were reported.

2.3. Data extraction and quality assessment

Study selection and data extraction were performed by two independent investigators. Unadjusted odds ratios or number of VTE events in each group, for studies reporting hazard ratios, were extracted and used for the analysis. Risk of bias was assessed in the RCTs by using the Cochrane tool [36] and in observational studies using the Newcastle-Ottawa tool [37].

2.4. Data synthesis and analysis

Random-effect model meta-analyses were used to estimate pooled odds ratio (OR) and 95% confidence intervals (CIs). Heterogeneity among studies was evaluated by the I² statistic. Forest plots and summary estimates were created for the overall analysis and stratified by study type and for men with and without a diagnosis of hypogonadism. A sensitivity analysis was performed using adjusted odds ratios. A funnel plot was created plotting the standard error of the log (OR) and the log (OR) to examine for publication bias.

3. Results

3.1. Search results

The search strategy identified 131 records, and after the title and abstract screening, 26 records underwent full-text review (Fig. 1). Five observational studies [2,11,38–40] and 6 RCTs [16,33,41–44] met criteria for inclusion in the quantitative analysis. Two meta-analyses examining testosterone and VTE were identified [45,46].

3.2. Description of included studies

Among the 5 observational studies, 2 were retrospective cohort studies, 2 were case-control studies, and 1 contained a retrospective cohort and a nested case-control study (Table 1). Data sources included commercial claims data, single institution academic medical center records, and governmental health data. The study by Martinez et al. [2] examined data from the United Kingdom; all others were conducted in patients from the United States. There were significant differences in study populations, number and type of covariates assessed, and stringency of VTE outcome definitions. All observational studies, except for the Ramasamy et al. [39] study, excluded patients with a history of VTE. The retrospective cohort and nested case-control study, by Li et al. [38], only reported associations with idiopathic VTE. For our analysis, we obtained unpublished data from the authors of this study reporting total VTE events to more closely match the definition of VTE in the...
other observational studies.

The 6 RCTs included a total of 2236 men (Table 2). The mean age in all RCTs was > 50 years and follow-up ranged from 3 to 12 months. Five trials were performed in men with documented hypogonadism [16,33,42–44] (by varying definitions—see Table 2). Five trials were double-blinded [16,33,41–43] and compared testosterone to placebo and one was open-label and compared testosterone to routine care [44]. The study in men without a diagnosis of hypogonadism [41] was performed in hospitalized men with alcohol-associated liver cirrhosis and compared oral micronized free testosterone to placebo. Brock et al. published two manuscripts on the same set of patients, one reporting the initial double-blind RCT with 3 months of follow up [47] and the other describing an open label 6-month extension within a subset of patients [44]. Only the open-label study reporting the longer follow up duration was included in our analysis. Patient exclusion criteria were extensive and varied significantly between RCTs, but no study specifically excluded patients with a history of VTE or a hypercoagulable condition. The risk of bias was overall moderate in this body of evidence. Specific risks of bias indicators are reported in Table 1 for observational studies and Table 2 for RCTs. One conference abstract was identified that did not show an association between testosterone and VTE in a population based study from British Columbia, Canada, but due to the inclusion criteria, was not included [48].

3.3. Meta-analysis results

The overall pooled OR in a random effects model including all studies found no statistically significant association between VTE and testosterone use (OR 1.41, 95% CI 0.96–2.07, I² = 84.4%; Fig. 2a). The analyses were also stratified by study design: RCTs (2.05, 95% CI 0.78–5.39), observational studies (cohort: 1.06, 95% CI 0.85–1.33 and case-control studies: 1.34, 95% CI 0.78–2.28; Fig. 2b). A sensitivity analysis performed using the adjusted odds ratio for studies performing multivariate adjustment also showed no significant association (OR 1.00, 95% CI: 0.93 to 1.08). The funnel plot analysis (Fig. 3) demonstrated asymmetry.

In recognizing that testosterone may be prescribed for conditions other than hypogonadism in men, we performed an additional analysis stratified by hypogonadism based on the individual definition of hypogonadism from each study (Fig. 2c). The studies by Li et al. and Baillargeon et al. could not be included because stratified VTE outcomes were not reported and were not obtainable from the authors. In this analysis, testosterone was associated with VTE both in men with and without a diagnosis of hypogonadism (OR 1.57, 95% CI 1.27–1.95 vs. OR 1.94, 95% CI 1.26–2.99). There was not a difference between these two groups (p = 0.39), suggesting no significant interaction (i.e., effect modification) between hypogonadism and VTE risk.

4. Discussion

This systematic review is the most comprehensive literature review on this topic and the meta-analysis including both RCTs and observational studies provide the best evidence available on the association between exogenous testosterone use in men and the risk for VTE. In the overall pooled OR of the 11 included studies, we did not find a significant association between testosterone and VTE. Results remained nonsignificant when using adjusted odds ratios. Two previous meta-analyses have examined VTE risk associated with testosterone use in RCTs. Xu et al. [45], examining only three RCTs, found an OR of 5.94 (95% CI 1.00–35.3) [49]. A more recent meta-analysis by Corona et al. [46] screened 2904 RCTs, and in the 6 studies included [16,33,41–44], found that testosterone was associated with an OR of 1.9 for VTE (95% CI 0.75–5.17), but the results were not statistically significant. Our search for RCTs ultimately identified the same studies, and our results were similar (2.05, 95% CI 0.78–5.39).

Testosterone-associated VTE may be a consequence of poorly selected candidates such as men without hypogonadism or with significant comorbidities. The use of testosterone in patients without hypogonadism is an important population to study the potential risks of therapy. Only one RCT identified in our systematic literature review evaluated this patient population. In the Copenhagen study [41], hospitalized men with alcoholic cirrhosis were randomized to micronized testosterone or placebo and when combined with patients without a diagnosis of hypogonadism from the Martinez et al. study, a statistically significant association between testosterone and VTE was identified. In this stratified analysis, there was also a significantly increased OR for
Table 1
Comparison of methods and results from observational studies evaluating the association between testosterone and VTE.

<table>
<thead>
<tr>
<th>Study type</th>
<th>Data source</th>
<th>Population</th>
<th>Exclusion criteria</th>
<th>Exposure/intervention</th>
<th>Outcome/case Definition</th>
<th>Sample size/ comparison</th>
<th>Analysis</th>
<th>Covariates included for multivariate model</th>
<th>Effect estimate for VTE</th>
<th>Strengths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li, 2016 [38]</td>
<td>MarketScan</td>
<td>Men with hypogonadism (ICD-9 or TT prescription)</td>
<td>History of VTE, continuous baseline insurance enrollment &lt; 12 months, age &lt; 18 years</td>
<td>Incident TT prescription</td>
<td>Idiopathic VTE by ICD-9 codes and review</td>
<td>102,650 treated and 102,650 untreated propensity score matched</td>
<td>Cox proportional hazard model</td>
<td>Age, infection(s), previous VTE, obesity, cardiovascular disorders, cancer, certain medication use.</td>
<td>Cox proportional hazard model and propensity score (SPIPTW)</td>
<td>Large sample size</td>
</tr>
<tr>
<td>Li, 2016 [38]</td>
<td>MarketScan</td>
<td>Men with hypogonadism (ICD-9 or TT prescription)</td>
<td>History of VTE, continuous baseline insurance enrollment &lt; 12 months, age &lt; 18 years</td>
<td>Incident TT prescription</td>
<td>Idiopathic VTE by ICD-9 codes and review</td>
<td>153 treated men and 64 untreated men with lower urinary tract symptoms</td>
<td>Conditional stepwise logistic regression model</td>
<td>Age, infection(s), previous VTE, obesity, cardiovascular disorders, cancer, certain medication use.</td>
<td>Overall VTE</td>
<td>Controlled for multiple important variables</td>
</tr>
<tr>
<td>Ramasamy, 2015 [39]</td>
<td>Single institution urology practice</td>
<td>Men with hypogonadism (total serum TT &lt; 300 ng/dL plus three or more hypogonadal symptoms)</td>
<td>Active malignancy, previous androgen deprivation therapy, TT prescription before age 65 years</td>
<td>Current TT exposure (Rx duration +90 washout period)</td>
<td>Thrombotic events (including VTE) by chart review</td>
<td>7643 cases with VTE and 22,424 controls</td>
<td>Logistic regression</td>
<td>None</td>
<td>OR 0.90 (0.73–1.12)</td>
<td></td>
</tr>
<tr>
<td>Baillargeon, 2015 [40]</td>
<td>Clinformatics DataMart</td>
<td>Men with commercial insurance</td>
<td>Age &lt; 40 years, &lt; 12 months continuous baseline insurance enrollment before index date, VTE or cancer in 12 months prior to index date, hospitalized &lt; 30 days or a prescription for anticoagulant &lt; 90 days before index event</td>
<td>Current TT exposure (Rx duration only)</td>
<td>VTE identified by ICD-9 codes plus anticoagulant or IVC filter</td>
<td>153 treated men and 64 untreated men with lower urinary tract symptoms</td>
<td>Multivariate conditional logistic regression</td>
<td>Covariates from the Elixhauser comorbidity index not balanced between the cases and controls and prescriptions for confounding medications</td>
<td>Overall RR 1.25 (0.94–1.66); ≤6 months TT: RR 1.63 (1.32–2.37); &gt; 6 months TT: RR 1.00 (0.68–1.47)</td>
<td>Strong definition of hypogonadism</td>
</tr>
<tr>
<td>Martinez, 2016 [2]</td>
<td>CPRD</td>
<td>Men in the United Kingdom</td>
<td>Age &lt; 20 or &gt; 89 years, &lt; 2 years up-to-standard history in CPRD before index date, previous VTE</td>
<td>Current TT exposure (Rx duration +30 day grace period)</td>
<td>VTE identified by ICD-9 codes plus anticoagulant prescription</td>
<td>19,215 cases with VTE, 909,530 controls</td>
<td>Multivariate conditional logistic regression</td>
<td>Baseline erythropoiesis, pulmonary disease, diabetes, CHF, MI, PVD, stroke, and history of prothrombotic disease</td>
<td>Overall RR 1.10 (0.78–1.54) and RR 1.14 (0.78–1.65)</td>
<td>Large sample size</td>
</tr>
<tr>
<td>Sharma, 2016 [11]</td>
<td>Veterans administrative corporate data warehouse</td>
<td>Men with low serum TT on at least two occasions</td>
<td>History of VTE, continuous baseline insurance enrollment &lt; 12 months, age &lt; 18 years</td>
<td>Incident TT prescription</td>
<td>VTE identified by ICD-9 codes</td>
<td>19,215 cases with VTE, 909,530 controls</td>
<td>Cox proportional hazard model</td>
<td>Age, body mass index, diabetes, CHF, and chronic kidney disease</td>
<td>'NorT' vs untreated (HR 1.10 (0.78–1.54) and RR 1.14 (0.78–1.65)</td>
<td>Strong definition of hypogonadism</td>
</tr>
</tbody>
</table>

Note: VTE = venous thromboembolism; HR = hazard ratio; OR = odds ratio; RR = relative risk; CI = confidence interval; TT = total testosterone; ICD-9 = International Classification of Diseases, Ninth Revision.
Table 1 (continued)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Li, 2016</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Li, 2016</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Ramasamy, 2015</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Baillargeon, 2015</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Martinez, 2016</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Sharma, 2016</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
</tbody>
</table>

**Abbreviations:** CHF = congestive heart failure, CPRD = Clinical Practice Research Datalink, HR = hazard ratio, ICD = International Classification of Diseases, IVC = inferior vena cava, LowT = low testosterone level on treatment, NorT = normal testosterone level on treatment, VTE = venous thromboembolism, MI = myocardial infarction, PVD = peripheral vascular disease, ROB = Risk of bias, RR = risk ratio, SIPTW = stabilized inverse probability of treatment weights, TT = testosterone.

**Selection bias**
- Low ROB: no statistically significant findings were observed.
- High ROB: significant findings were observed.
- Unclear: the risk of bias could not be determined.

**Comparability**
- Low ROB: the studies were considered comparable.
- High ROB: the studies were considered non-comparable.
- Unclear: the comparability of the studies was unclear.

**Outcome assessment**
- Sufficient data: the outcomes were assessed with sufficient data.
- Limited data: the outcomes were assessed with limited data.
- No data: the outcomes were not assessed.

**Limitations**
- Small sample size
- Selection bias
- Confounding by indication
- Single center study
- Limited number of covariates

**Results**
- TT treatment
  - Due to exclusion criteria would not be included in the United Kingdom vs. United States comparison.
  - Use of only ICD-9 definition for VTE less specific.
  - Confounding by indication for TT treatment.
  - Study performed by Eli Lilly and Co. investigators.
  - Coauthor received funding from Eli Lilly and TestoRx.

**Conclusion**
- The route of testosterone administration has also been investigated regarding thrombotic risk because of inherent differences in pharmacokinetics. Intramuscular injection use is associated with higher peak and lower trough plasma drug concentrations, while transdermal gel and patch testosterone formulations provide more consistent daily levels. The testosterone market in the United States and the United Kingdom has been rapidly shifting towards gel formulations and away from injection and patch use [3]. No randomized control trial in our

VTE in men with hypogonadism and the test for interaction did not demonstrate a significant difference in the association between the groups. This finding is discrepant from our overall analysis, which did not find a statistically significant association. Two of the observational studies could not be included in this additional analysis due to insufficient data, and therefore the significance of these findings compared to the overall analysis is uncertain. It does demonstrate the consequences of a limited data pool and suggests that additional large studies could significantly influence the balance of the association. Notably, removal of studies that did not stratify their results by hypogonadism significantly reduced the heterogeneity between the remaining studies, indicating that confounding by this variable may have been present. The discrepancy between the overall analysis and stratified analyses also suggests the presence of other important confounders.

It is important to realize that even if no statistical difference in VTE has been identified in the meta-analysis of RCTs, the analyzed RCTs would not be able to detect significant differences in VTE given the limited number of patients studied. The available data is currently inadequate and should not be interpreted as “negative,” and in fact is potentially consistent with an increased risk. Assuming a baseline rate of VTE of approximately 30 per 10,000 person-years for men 60–64 years old [50,51], identifying a significant risk ratio of 1.5 (RR = 1.5) would require 15,613 subjects per group (testosterone and placebo). Thus, the currently available randomized studies may simply be underpowered to detect an increased VTE risk in testosterone users. Clinically, if a statistically significant VTE risk with testosterone were demonstrated in an adequately powered study, an RR of 1.5 – while possibly considered a “mild” VTE risk – could be clinically meaningful, as it would translate to one additional VTE event for every 400 men treated [number needed to harm (NNH) = 400]. Oral contraceptive therapy in younger women, by point of comparison, is associated with a RR of 4.17 for VTE [52], and a NNH of 1048.

In general, subjects in RCTs tend to be healthier than average due to extensive exclusion criteria, have higher medication adherence rates, and have more frequent evaluations than those receiving routine care in observational studies and one might suspect lower rates of VTE in these trials. Well-designed observational studies could provide useful information on real-world outcomes, especially when data from RCTs is limited. Important differences in patient populations between RCTs and observational studies were observed in this review and important confounding variables were not uniformly assessed. One important difference between observational studies and RCTs was that observational studies largely excluded patients with a history of VTE. Another potential difference between randomized and observational studies is medication adherence. If testosterone treatment discontinuation is high in clinical practice, extended follow-up of patients in retrospective cohort studies who discontinued testosterone, but continue to contribute exposed person time, would potentially dilute the adverse events occurring in the continually exposed group (assuming adverse events are not late sequelae of treatment). Data does suggest that only 17% of new-users of testosterone continuously use testosterone for one full year, while 23% discontinue after the first prescription and 18% discontinue after the second prescription [53]. This could contribute to differences between randomized control trials and observational studies.

### 4.1. Route of administration

The route of testosterone administration has also been investigated regarding thrombotic risk because of inherent differences in pharmacokinetics. Intramuscular injection use is associated with higher peak and lower trough plasma drug concentrations, while transdermal gel and patch testosterone formulations provide more consistent daily levels. The testosterone market in the United States and the United Kingdom has been rapidly shifting towards gel formulations and away from injection and patch use [3]. No randomized control trial in our
### Table 2
Comparison of randomized control trials.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Study size</th>
<th>Mean age</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Intervention</th>
<th>Masking</th>
<th>Follow up duration</th>
<th>VTE events</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of participants and personnel</th>
<th>Blinding of outcome assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copenhagen, 1986 [41]</td>
<td>N = 221</td>
<td>53 years</td>
<td>Hospitalized men, daily ethanol consumption &gt; 50 g for &gt; 2 years, cirrhosis diagnosed by liver biopsy within 6 months</td>
<td>Malignancy, Hepatitis infection, Klinefelter’s syndrome, unable to cooperate</td>
<td>Micronized-free testosterone (600 mg daily) (n = 134) vs. placebo (n = 87)</td>
<td>Double-blind</td>
<td>3 years</td>
<td>Gel testosterone = 1 Placebo = 0</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Marin, 1993 [33]</td>
<td>N = 31</td>
<td>58 years</td>
<td>Men age &gt; 40 years, abdominal obesity (WHR &gt; 0.9), BMI &lt; 35, serum total testosterone &lt; 20 nmol/L (577 ng/dL), stable weight</td>
<td>Prostate enlargement or elevated PSA (&gt; 3.0 mg/L), diabetes mellitus, hypertension, alcohol abuse</td>
<td>Testosterone gel vs. DHT gel vs. placebo gel (n = 130) vs. placebo gel (n = 132)</td>
<td>Double-blind</td>
<td>9 months</td>
<td>Gel DHT = 0 Placebo = 0</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Srinivas-Shankar, 2010 [42]</td>
<td>N = 274</td>
<td>74 years</td>
<td>Men ≥65 years, frailty, low morning total testosterone &lt; 345 ng/dL or free T &lt; 7.2 ng/dL</td>
<td>Prostate cancer, IPSS score &gt; 21, PSA &gt; 4 ng/mL, creatinine &gt; 180 mmol/L, active liver disease, moderate to severe pad, severe COPD, CHF (NYHA ≥ 2), angina requiring nitrates, untreated sleep apnea, major psychiatric illness, certain medications, stroke, MMSE score &lt; 18, active disease of muscle or joint</td>
<td>Testosterone gel (n = 130) vs. placebo gel (n = 132)</td>
<td>Double-blind</td>
<td>6 months</td>
<td>Testosterone = 1 Placebo = 0</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Behre, 2012 [43]</td>
<td>N = 362</td>
<td>62 years</td>
<td>Men 50–80 years old, symptomatic hypogonadism, AMS score &gt; 36, total testosterone &lt; 430 ng/dL, free testosterone &lt; 193 ng/dL</td>
<td>BMI &gt; 35 kg/m², PSA ≥ 4 ng/mL, IPSS ≥ 20, prostate cancer, hematocrit &gt; 50%, prostatic &gt; 25 mg/mL, metallic implants, cytochrome P450 inducing medications, psychiatric disorders, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, HTN, epilepsy, severe cardiac, hepatic, or renal insufficiency</td>
<td>Testosterone gel (n = 183) vs. placebo gel (n = 179)</td>
<td>Double-blind</td>
<td>6 months</td>
<td>Testosterone = 1 Placebo = 0</td>
<td>Low ROB</td>
<td>High ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Brock, 2016 [44]</td>
<td>N = 558</td>
<td>55 years</td>
<td>Men ≥ 18, 2 total testosterone levels &lt; 300 ng/dL, symptomatic hypogonadism</td>
<td>Hemoglobin A1c &gt; 11%, BMI &gt; 37 kg/m², hematocrit &gt; 50%, active cancer, PSA &gt; 4 ng/mL</td>
<td>Testosterone gel (n = 394) vs. placebo gel (n = 394)</td>
<td>Double-blind</td>
<td>12 months</td>
<td>Testosterone = 2 Placebo = 2</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
<td>Low ROB</td>
</tr>
<tr>
<td>Snyder, 2016 [16]</td>
<td>N = 790</td>
<td>72 years</td>
<td>Men age &gt; 65 years, serum testosterone &lt; 275 ng/dL, symptoms of hypogonadism</td>
<td>History of prostate cancer, high risk of prostate cancer by Prostate Cancer Risk Calculator, an IPSS &gt; 19, conditions known to cause hypogonadism, medications that alter testosterone concentration, high cardiovascular risk, severe depression, “other conditions that would affect the interpretation of the results”.</td>
<td>Topical 2% testosterone (n = 282) vs. observation (n = 275)</td>
<td>Open-label</td>
<td>6 months</td>
<td>Observation = 0</td>
<td>Low ROB</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low ROB</td>
</tr>
</tbody>
</table>

Abbreviations: AMS = Aging Males Symptoms, BMI = body mass index, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, DHT = dihydrotestosterone, HTN = hypertension, IPSS = International Prostate Symptom Score, MMSE = Mini Mental Status Examination, Prostate Symptom Score, PSA = prostate antigen, ROB = risk of bias, WHR = waist-hip ratio.
systematic review evaluated patients treated with intramuscular testosterone. Oral testosterone is infrequently prescribed in clinical practice but one RCT included in our review did use it.

One study has specifically compared the risk of VTE by route of testosterone administration (gel, patch, injection) in a new-user retrospective cohort [54]. Using multiple data sources (MarketScan, Medicare, Clinical Practice Research Datalink (CPRD)), the investigators identified 544,115 testosterone initiators and evaluated cardiovascular events (including VTE) for up to one year. Although an increase in cardiovascular and cerebrovascular events was found in injection users compared to gel users, no increased risk was found for VTE (HR 0.92, 95% CI 0.76–1.11). This finding is also consistent with four studies identified in this review [2,11,38,40] that also did not find an association between VTE and any specific route of testosterone administration.

4.2. Limitations

Thousands of randomized control trials have been performed with various formulations of testosterone, but unfortunately, most have not
Clinical Management Considerations

No strong recommendations can be made regarding the risk of VTE or the management of VTE in testosterone users given the currently available data. However, based on existing data and our best clinical judgment our treatment approach and recommendations are as follows:

A. When considering testosterone therapy:
1. Adhere to the Endocrine Society Clinical Practice Guideline\(^1\) regarding treatment indications, testosterone dosing, and monitoring.
2. Assess a patient’s risk factors for VTE prior to initiation of testosterone therapy (previous VTE, age, active smoking, body mass index, malignancy, immobility, VTE family history, etc.). Do not routinely order thrombophilia evaluations.
3. Avoid testosterone therapy in a patient at high risk for VTE (active malignancy, prior history of VTE and not on anticoagulation, known strong inherited thrombophilia, planned major surgery)
4. Counsel patient on the risks associated with testosterone therapy, including possible risk for VTE; educate about VTE symptoms.

B. When evaluating a patient with VTE:
1. Ask about the use of testosterone, ‘supplements’ that may contain testosterone derivatives, and anabolic steroids.
2. When deciding how long to anticoagulate a patient who develops VTE while on testosterone, consider all VTE risk factors, length of time the patient has been on testosterone, presence of erythrocytosis, on-treatment serum testosterone level if available, benefits and risks of ongoing testosterone therapy, risk of bleeding, patient management preference, and cost/burden of anticoagulation.
3. Provoked VTE: For patients on testosterone with VTE associated with a major provoking factor (surgery, hospitalization), we recommend short-term anticoagulation +/- testosterone discontinuation.
4. Unprovoked VTE: For patients on testosterone with unprovoked VTE, or VTE in the setting of a ‘minor’ provoking factor, we tend to prefer long-term anticoagulation. However, we consider short-term anticoagulation for patients with erythrocytosis associated VTE, or VTE occurring within 6 months of testosterone initiation (based on the Martinez et al. [2] study) who are willing/able to discontinue testosterone therapy, particularly if D-dimer testing (on and off anticoagulation) is reassuring.

Fig. 4.

specifically reported VTE outcomes. High heterogeneity was seen in the overall pooled OR, limiting the interpretation of the summary estimate. The safety data for randomized trials evaluating testosterone is limited to relatively short-term follow up (up to 12 months) and no RCTs included use of intramuscular injections of testosterone. Among the observational studies, differences in study design, covariates assessed, ability to control for confounding, varying lengths of follow up, and different criteria to assess VTE outcomes significantly limit definitive conclusions on the association between testosterone and VTE. The funnel plot demonstrated significant asymmetry which may represent publication bias, but the test is not reliable when the number of studies is small or when heterogeneity is present. Asymmetry could also indicate selective outcome or analysis reporting, poor methodologies, or true heterogeneity among the studies included.

The study by Martinez et al. [2] did find an increased risk of VTE when examining outcomes after an initial six months of treatment (RR 1.63, 95% CI 1.12–2.37), but not in the overall follow up data, potentially indicating a healthy user bias for more long-term users. We were not able to perform additional sensitivity analyses regarding duration of follow up. Erythrocytosis as it relates to VTE was not reported or not considered in most of the studies included in the analysis; therefore it remains unclear to what extent testosterone-induced erythrocytosis may be associated with VTE. Varying definitions of hypogonadism between studies could reduce the ability to determine differences between these groups in the stratified analysis. Confounding by indication is a major limitation of retrospective cohort studies that compare patients treated, versus not treated with testosterone. Additionally, the analyses performed as “intent-to-treat”, although ideal for preventing biased treatment effect measures, may bias safety data towards the null. No consensus exists on how to best manage patients with VTE occurring while taking testosterone [55]; therefore, we propose an approach based on the available evidence and observations from clinical practice (Fig. 4).

5. Conclusion

This systematic review and meta-analysis did not show a significant association between testosterone use and VTE in men. The analysis highlights the scarcity of high-quality research on this topic, preventing any definitive conclusions. Testosterone therapy remains a very active area of research and we urge all future clinical trials to specifically report VTE as an outcome. Additional observational studies will be critical to fully evaluate the risk of testosterone outside of clinical trials and these should focus on new-users of testosterone to identify time-varying hazards, capture early events, reduce healthy user bias, and
correctly time covariate assessment. If an increase in VTE with testosterone is demonstrated in future studies, we must understand what groups are at the highest risk and if there are clinically apparent mediators of VTE that can be modified to minimize the risk.

Acknowledgements

Prior presentations: Data from this manuscript was presented at the International Society of Thrombosis and Haemostasis conference in Dublin, Ireland in July 2018. This work was supported by the National Heart, Lung, Blood Institute [Grant # 5T32HL007149-39].

Disclosure statement

JBL is an employee of RTI International, an independent, non-profit research organization that performs contact work on behalf of government agencies and pharmaceutical companies.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.thromres.2018.10.023.

References


